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It has been suggested that toxic oxygen free radicals can
be involved in the pathogenesis of systemic sclerosis
(scleroderma) (SSc). Because the cells that contribute
to the generation of free radicals are not known, our
aim was (i) to evaluate the ability of unmanipulated and
phorbol 12-myristate 13-acetate-stimulatedmonocytes
and polymorphonucleate neutrophils of SSc patients to
generate superoxide anion (O2·–); and (ii) to investigate
whether the O2·– produced by these cells involved
the activation of nicotinamide-adenine dinucleotide
diphosphate oxidase biochemical pathway. Employing
the superoxide dismutase-inhibitable reduction of
cytochrome c to evaluate the generation of O2·–,
unmanipulated monocytes of SSc patients generated
more O2·– than primary Raynaud’s phenomenon
patients and normal control monocytes (p J 0.0001),
and the release was higher in patients with diffuse cuta-
neous involvement and 5 y or less disease duration
(p J 0.02). The involvement of nicotinamide-adenine
dinucleotide diphosphate oxidase in the enhanced O2·–
production was demonstrated by the finding that the
cytosolic components of the enzyme, p47phox and
Systemic sclerosis (scleroderma) (SSc) is the clinical mani-festation of several interacting factors that culminate inabnormal fibrosis of the skin and internal organs (Kriegand Meuer, 1988; Black and Stephens, 1993). The highprevalence of Raynaud’s phenomenon (Belch, 1989;
Belch, 1991) and of nailfold capillaroscopy abnormalities (Maricq
and LeRoy, 1979), and histologic evidence of microvascular injury
(Fleischmajer et al, 1976; Rodnan et al, 1980; Prescott et al, 1992),
suggest that vascular involvement is one of the main events in the
pathogenesis of scleroderma. The factors implicated in vascular
derangement in SSc patients are unknown. Likely candidates are
considered to be the soluble mediators secreted by cells of the
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p67phox, were both translocated to the plasma
membrane of enriched but otherwise unmanipulated
monocytes of SSc patients. The involvement of
mitochondrial oxidases was excluded by the lack of
inhibition of O2·– production when monocytes were
incubated in the presence of rotenone, a mitochondrial
oxidase inhibitor. Upon stimulation with phorbol
12-myristate 13-acetate, monocytes of SSc patients
produced more O2·– than controls. In SSc patients
untreated polymorphonucleate neutrophils generated
significantly less O2·– than monocytes (p J 0.0001) and
only slightly more than polymorphonucleate neutro-
phils of primary Raynaud’s phenomenon patients and
normal controls (p J 0.03). In conclusion, we demon-
strate that in patients with scleroderma, unmanipulated
andphorbol 12-myristate 13-acetate-stimulatedmono-
cytes release in vitro increased amounts of superoxide
anion through the activation of nicotinamide-adenine
dinucleotide diphosphate oxidase and, thus, contribute
to the oxidative stress found in this disease. Key words:
connective tissue disease/free radicals/monocyte/scleroderma.
J Invest Dermatol 112:78–84, 1999
immune system, IL-1, IL-2, tumor necrosis factor (TNF)-α,
transforming growth factor (TGF)-β, platelet derived growth factor
(PDGF), and leukotrine B4, reported to be present in high amounts
in SSc patients, directly or indirectly could alter functions of
vascular cells (White, 1996). Although supported by little evidence
to date, it has also been suggested that antibodies might contribute
to endothelial cell alteration or damage through direct binding
(Salojin et al, 1997) or antibody-dependent cellular cytotoxicity
(Marks et al, 1988; Holt et al, 1989). Lastly, granzyme A, a serine
protease released by cytolytic CD81 T cells and found in SSc skin,
may be the factor in SSc serum that is cytotoxic to the endothelial
cells (Kahaleh and LeRoy, 1983).1,2 With regard to nonimmune
mechanisms, the main mediators of cytotoxicity of endothelial cell
1Kahaleh MB, Yin T: The molecular mechanism of endothelial cell
(EC) injury in scleroderma (SSc): identification of granzyme 1 (a product
of cytolytic T cell) in SSc sera. Arthritis Rheum 33:S21, 1990 (abstr.)
2Kahaleh MB, Fan PS: Cytotoxic T cell involvement in scleroderma
(SSc): detection of granzyme A gene expression in SSc skin. Arthritis Rheum
35:S38, 1992 (abstr.)
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Table I. Clinical characteristics of patients
Median age, Median duration of Raynauld’s Median duration of
Group No. M/F y (range) phenomenon, mo (range)a disease, mo (range)b Subset lSSc/dSScc
SSc 29 7/22 57 (21–77) 96 (24–360) 48 (12–322) 21/8
PRP 10 3/7 39 (14–61) 70 (32–40) 70 (32–40) –
Healthy controls 21 7/14 42 (26–67) 0 0 –
aFrom onset of symptoms.
bFrom diagnosis of systemic sclerosis (scleroderma).
clSSc, limited scleroderma; dSSc, diffuse scleroderma (LeRoy et al, 1988).
injury are considered to be free radicals (Murrel, 1993), because
microvascular endothelial cells have an impaired capacity to syn-
thesize the enzyme catalase (Shingu et al, 1985), a free radical
scavenger, and are thus particularly prone to reactive oxygen
species-mediated injury.
Excessive oxidative stress has been implicated in SSc as deter-
mined by increased plasma levels of malondialdehyde (a measure
of free radical activity) (Lau et al, 1992) and higher urinary
concentration of the bioactive F2-isoprostanes (peroxidation
products of arachidonic acid) (Stein et al, 1996). Bruckdorfer et al
(1995) showed that low density lipoproteins from scleroderma
patients were more susceptible to oxidation than those from healthy
controls and concluded that free radical damage is involved in SSc.
Additionally, low serum levels of selenium and ascorbic acid have
been described in patients with scleroderma and with primary
Raynaud’s phenomenon (Herrick et al, 1994). These findings
suggest that a concurrent antioxidant deficiency could contribute
to the oxidative damage observed in scleroderma.
It is therefore conceivable that an enhanced production of
reactive oxygen intermediates, a decreased defence against the
oxygen free radicals, or both, can play an important role in the
pathogenesis of scleroderma; however, it has not been elucidated
which cell type and which biochemical reactions are involved in
the production of such radicals in SSc patients.
Free radicals are generated during many biologic processes by
mitochondria, and enzymatic reactions of xanthine oxidase, alde-
hyde oxidase, flavin dehydrogenase generate superoxide. A possible
source of toxic oxygen derivatives in blood vessels is the nico-
tinamide-adenine dinucleotide diphosphate (NADPH) oxidase that
is expressed in phagocytic cells. This enzymatic system is composed
of various proteins, some located on the cell membranes (the
subunits of the cytochrome b558, gp91
phox and p22phox) and others
in the cytosol (p47phox and p67phox) (De Leo and Quinn, 1997).
The activation of NADPH oxidase involves the translocation of
p47phox and p67phox from cytosol to the plasma membrane, where
they interact with the cytochrome b558 to form an electron
transport chain that transfers electrons from intracellular NADPH
to extracellular oxygen (Clark et al, 1990; De Leo and Quinn, 1997).
In this study we present data demonstrating an increased genera-
tion of oxygen free radicals by both unmanipulated and phorbol 12-
myristate 13-acetate (PMA)-stimulated monocytes of SSc patients.
Here we also show that the NADPH oxidase of monocytes is
involved in the production of oxygen free radicals in scleroderma
patients.
MATERIALS AND METHODS
Patients Twenty-nine nonsmoking scleroderma patients (seven men and
22 women) with a median age of 57 y (range 21–77) were studied. The
prevalence of female SSc patients is in agreement with the female to male
ratio between 3 and 8:1 already reported (Silman, 1997). The clinical
features of the study populations are presented in Table I. Diagnosis was
made following the ACR criteria (Masi et al, 1980) and the patients were
classified into the diffuse SSc and limited SSc subset according to LeRoy
et al (1988). Moreover, patients within the diffuse SSc subset were divided
into patients with early disease (5 y or less of disease duration) and
patients with late disease (more than 5 y of disease duration) (Steen and
Medsger, 1990).
At the time of the investigation the patients, who had never been on
imunosuppressive therapy, had not received any treatment for the previous
6 wk.
Because Raynaud’s phenomenon may precede by years the development
of scleroderma, 10 patients with primary Raynaud’s phenomenon (PRP)
(three men and seven women), were included in the study (Table I).
Diagnosis of PRP was made according to the criteria reported elsewhere
(LeRoy and Medsger, 1992).
Twenty-one age, sex, and race matched, normal, nonsmoking, healthy
volunteers were also evaluated and constituted the control population.
Blood was taken from patients and controls after acclimatization at 21°C
for 30 min.
Cells Monocytes and polymorphonucleate neutrophils (PMN) were
enriched from 100 ml of freshly drawn venous blood collected into sterile,
pyrogen-free, vacuum blood collection tubes using heparin (10 U per ml
blood) as anticoagulant, as described elsewhere (Bertani et al, 1989).
Aliquots of 15 ml of heparinized blood diluted 1:2 with pyrogen-free
phosphate-buffered saline were placed on 15 ml of Ficoll-Hypaque (Sigma,
St Louis, MO) for centrifugation at 400 3 g for 25 min at room temperature,
to allow separation of mononuclear cells from PMN and red blood
cells. Mononuclear cells collected at the interface were washed twice in
phosphate-buffered saline at 200 3 g to remove platelets and separated into
lymphocytes and monocytes by 47% Percoll (Pharmacia, Uppsala, Sweden)
gradient centrifugation at 600 3 g for 30 min at 4°C. Under the described
experimental conditions electron microscopy study of monocytes excluded
internalization of Percoll particles that could be responsible for nonspecific
cell activation (data not shown). PMN recovered from the top of the red
cell pellet after Ficoll-Hypaque centrifugation were enriched by a 67%
Percoll gradient centrifugation at 400 3 g for 20 min at 4°C. Monocyte
and PMN populations were .95% pure as assessed by nonspecific esterase
staining and May-Grunwald-Giemsa staining, respectively. The monocyte
and PMN fractions were placed into separate 15 ml test tubes, diluted in
ice-cold Krebs-Ringer phosphate buffer with glucose, prepared as described
(De la Harpe and Nathan, 1985), and kept in ice until use.
Superoxide anion assay Superoxide anion release, from unmanipulated
and PMA-activated cells, was estimated using the superoxide dismutase-
inhibitable cytochrome c reduction (Weening et al, 1975; Markert et al,
1984). Briefly, 1.5 3 106 cells were placed in 1.5 ml polypropylene
microfuge test tubes and incubated in Krebs-Ringer phosphate buffer with
glucose, pH 7.4, containing 80 µM of ferricytochrome c (type III; Sigma),
with and without superoxide dismutase (Sigma) (300 U per ml, final
concentration), in the presence or absence of PMA (Sigma) (100 ng per
ml, final concentration), in a total volume of 1 ml. After incubation for
30 min at 37°C, the reaction was stopped by placing the tubes in melting
ice and the absorbance of the supernatant was read at 550 nm. An extinction
coefficient of 21.0 3 103 per M per cm was used for oxidized versus
reduced cytochrome c. In selected experiments, to determine whether a
functional NADPH-oxidase complex was involved in the generation of
O2·
–, monocytes were treated with 20 µM of diphenylene iodonium, a
potent and highly selective flavoprotein inhibitor, for 30 min before
evaluation of superoxide anion generation. To investigate whether mito-
chondrial oxidase had any role in the production of O2·
–, monocytes were
incubated with 50 µM of rotenone, a mitochondrial oxidase inhibitor, for
30 min. Results are expressed as nmol O2·
– per 30 min per 106 cells.
Preparation of monocyte cell membranes and cytosols To analyze
the membranes of monocytes of individual patients and controls, monocytes,
separated as described above, were pretreated with 1 mM di-isopropyl
fluorophosphate (Sigma) for 5 min at 4°C, washed, resuspended in Krebs-
Ringer phosphate buffer with glucose and activated with 100 ng PMA per
ml or treated with the solvent alone (0.01% dimethylsulfoxide) for 30 min
at 37°C. The cells were then frozen and kept in liquid nitrogen until use.
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The membranes of monocytes were isolated as previously described (Abo
et al, 1994; Dusi et al, 1996). Briefly, unmanipulated and PMA-activated
monocytes were thawed, washed with RPMI 1640, and resuspended in
0.4 ml of ice-cold relaxation buffer [100 mM KCl, 3 mM NaCl, 3.5 mM
MgCl2, 1.25 mM ethyleneglycol-bis(β-aminoethyl ether)-N,N,N9,N9-
tetraacetic acid, 10 mM Pipes pH 7.3] containing 5 µg leupeptin per ml,
5 µg pepstatin per ml, 10 µM phenylarsine oxide, 2 mM sodium
orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 5 mM sodium fluoride
(all from Sigma). Cells were then disrupted by two cycles of sonication
for 30 s at 100 W using a Labsonic 1510 sonicator. Unbroken cells and
nuclei were pelleted by centrifugation at 500 3 g for 10 min at 4°C. The
supernatant was carefully layered on the top of a discontinuous sucrose
gradient of 1.5 ml of 15% (wt/wt) sucrose on 1.5 ml of 34% (wt/wt)
sucrose made up in relaxation buffer, and centrifuged at 100,000 3 g for
40 min at 4°C in a Beckman L5–50B ultracentrifuge using a SW50 rotor.
The light membrane fractions were collected at the 15%–34% sucrose
interface, washed in cold relaxation buffer, and pelleted by ultracentrifuga-
tion at 100,000 3 g for 30 min at 4°C. Membranes were resuspended in
electrophoresis sample buffer [60 mM Tris/HCl, 20% (vol/vol) glycerol,
4% (wt/vol) sodium dodecyl sulfate (SDS), 2% (vol/vol) 2-mercaptoethanol,
pH 6.8] and boiled for 5 min at 100°C. The protein content was measured
with the Bio-Rad Protein assay (Bradford, 1976).
Electrophoresis and immunoblotting Aliquots of monocyte mem-
branes of individual patients and controls containing the same amount of
protein (25 µg) were subjected to SDS/polyacrylamide gel electrophoresis
on 12% gels, according to standard procedures. Proteins were transferred
from the gels to nitrocellulose membranes (Bio-Rad, Milan, Italy) using a
Bio-Rad Trans Blot Cell apparatus. Blotting was performed at 70 V for
90 min in 25 mM Tris, 192 mM glycine, 20% (vol/vol) methanol, 3.5 mM
SDS, pH 8.3 at 4°C. To ensure that comparable amounts of proteins had
been transferred to the nitrocellulose membranes, proteins were revealed
on the nitrocellulose membranes by staining with 0.05% (vol/vol) Ponceau
S (Sigma) for 1 min. The blots were then rinsed in TBS [50 mM Tris,
170 mM NaCl, 0.2% (vol/vol) Tween 20, pH 7.5] and incubated for
90 min in TBS containing 5% bovine serum albumin (blocking buffer),
before incubation overnight at 4°C with rabbit anti-p47phox antibodies
(kindly provided by Dr. F. Wientjes, Department of Medicine, University
College, London, U.K.), diluted 1:500 in TBS containing 1 mg bovine
serum albumin per ml. The blots were rinsed with several changes of TBS
and then incubated for 60 min at room temperature in a horseradish-
labeled donkey anti-rabbit IgG (Amersham, Little Chalfont, U.K.) diluted
1:15,000 in TBS containing 1 mg bovine serum albumin per ml. After
further washing, bound antibodies were detected using enhanced chemilu-
minescence, western blotting detection reagents (Amersham). The blots
were rinsed with TBS and stripped for 30 min at 50°C in a solution
containing 100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl
pH 6.7. This treatment removed both primary and secondary bound
antibodies, and allowed us to reuse the blots with a different primary
antibody. After washing with an excess of TBS, the blots were incubated
with rabbit anti-p67phox antibodies (also provided by Dr. F. Wientjes),
diluted 1:500 in TBS containing 1 mg bovine serum albumin per ml.
All the subsequent steps were performed as described for the anti-
p47phox antibody.
Flow cytometry analysis Monocytes were enriched from peripheral
blood as described above, washed with phosphate-buffered saline, and
incubated at 4°C for 30 min with monoclonal antibody against CD11a,
CD11b, and CD11c β2 integrins, followed by washing and labeling with
an FITC-conjugated rabbit F(ab)92 anti-mouse IgG (Dakopatts, Glostrup,
Denmark). Samples were analyzed by flow cytometry in a FACScan
cytofluorometer (Becton Dickinson).
Statistical analysis Due to the non-normal distribution of data, the
Mann–Whitney U and the Wilcoxon test were employed for the compar-
ison of unpaired and paired data, respectively. Values of p , 0.05 are
considered statistically significant.
RESULTS
Unmanipulated monocytes of SSc patients release increased
amounts of superoxide anion Figure 1 shows the amounts of
superoxide anion generated by unmanipulated monocytes of nor-
mal, PRP, and SSc patients expressed as nmol of O2·
– per 30 min
per 106 cells. The median amount of superoxide released by
unmanipulated monocytes of SSc patients (1.63 nmol per 30 min
per 106 cells; 95% confidence interval, 1.0–3.2) is significantly
Figure 1. Unmanipulated monocytes of scleroderma patients
generate higher amounts of superoxide than PRP patients and
normal controls. N, healthy controls. Solid and open symbols indicate
female and male patients, respectively. The horizontal bars indicate the
median values.
Table II. Phenotypic expression of b2 integrins is similar
on monocytes from SSc patients and normal controlsa
No of
Group patients CD11a CD11b CD11c
SSc 4 155.8 6 18.3 103 6 12.7 190.7 6 68.2
Healthy controls 4 206.4 6 16.8 110.8 6 32.8 182.9 6 32.5
aExpressed as mean 6 SD. All the comparisons are not statistically significant.
greater (p 5 0.0001) than the amount generated by cells of PRP
patients (median value, 0; 95% confidence interval, 0–0.12) and by
normal monocytes (median value, 0; 95% confidence interval, 0–
0.47). The difference between patients with PRP and normal
controls is not significant (p 5 0.4). Using the ninetieth percentile
as the upper limit of normal values, 82.7% of scleroderma patients
but only 9.5% of healthy subjects and none of PRP patients display
elevated levels of O2·
– release. No significant difference is found
when male SSc patients are compared with female SSc patients
(data not shown) and no correlation is demonstrated between the
extent of organ involvement and O2·
– production (data not shown).
To exclude the possibility that the generation of oxygen free
radicals measured was due to cell adhesion to the wall of the test
tubes, the release of superoxide anion was also evaluated in test
tubes pretreated with silicone. The amount of superoxide released
by SSc monocytes in siliconized tubes is comparable with that
obtained in untreated tubes (data not shown). Furthermore, the
expression of β2-integrins by monocytes of SSc patients is not
significantly different from that detected in control cells (Table II).
This finding rules out a potential mechanism of homotypic cell
aggregation in the generation of superoxide anion (Dusi et al, 1996).
We then investigated the relationships between the amount of
superoxide anion generated by unmanipulated monocytes and the
clinical features of scleroderma patients. As Table III indicates, no
difference is detected when all patients are divided into the limited
or the diffuse subset, or into early (5 y or less) or late (over 5 y)
disease. In contrast, within the diffuse subset there is a significant
difference between patients with early disease and those with late
disease (p 5 0.02).
In scleroderma patients unmanipulated polymorphonucleate
neutrophils release less superoxide anion than mono-
cytes When unmanipulated PMN are analyzed, the median
amount of superoxide released from scleroderma cells is 0.06 nmol
O2·
– per 30 min per 106 cells (95% confidence interval, 0–0.29)
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Figure 2. Unmanipulated PMN of scleroderma patients generate
higher amounts of superoxide than healthy controls. The difference
between scleroderma and PRP monocytes was not statistically significant.
Scleroderma PMN generate significantly less O2·
– than monocytes. This is
evident once the different scale employed to plot PMN data is taken into
account. N, healthy controls. Solid and open symbols indicate female and
male patients, respectively. The horizontal bars indicate the median values.
Table III. Monocyte production of superoxide is higher in
SSc patients with early, diffuse cutaneous SSc
No of O2·
– per 30 min per 106
Subset patients monocytes median (range) p
lSSca 21 2.00 (0–52) ] 0.73dSSc 8 1.27 (0–4.07)
Early SScb 17 2.5 (0–5.2) ] 0.13Late SSc 12 1.08 (0–3.9)
Early dSScc 4 3.6 (1.05–4.07) ] 0.02Late dSSc 4 0.8 (0–1.05)
alSSc, limited scleroderma; dSSc, diffuse scleroderma (LeRoy et al, 1988).
bAll SSc patients are divided in early (5 y or less of disease duration) and late
(more than 5 y of disease duration) SSc.
cPatients with diffuse cutaneous SSc (LeRoy et al, 1988) were divided into patients
with early (5 y or less of disease duration) or late (more than 5 y of disease
duration) disease.
and the only difference found is between SSc and healthy controls
(p 5 0,03) (Fig 2). Nine per cent of SSc patients and 2% of PRP
and of normal subjects are above the ninetieth percentile. In SSc
patients, PMN generated significantly less O2·
– than monocytes
(p 5 0.0001), and no correlation was found between the amounts
of superoxide anion produced by monocytes and the amounts of
O2·
– generated by PMN.
NADPH oxidase is activated in unmanipulated monocytes
of scleroderma patients To understand whether NADPH
oxidase is involved in the production of superoxide anion by
unmanipulated monocytes of SSc patients, we have analyzed the
translocation of the cytosolic components p47phox and p67phox to
the plasma membrane of these cells, a step that is essential for the
activation of the enzyme (Clark et al, 1990; De Leo and Quinn,
1997). For this purpose we have fractionated resting monocytes
from five consecutive normal controls and 10 consecutive SSc
patients releasing high levels of superoxide, and we have immuno-
blotted the light membrane fractions of these cells with antibodies
raised against p47phox and p67phox. Two representative experiments
are shown in Figs 3 and 4. As compared with monocytes of
control donors, an increased translocation of both p47phox and
p67phox is evident in unmanipulated cells from scleroderma patients.
To further assess the involvement of NADPH oxidase in the
Figure 3. Activation of NADPH oxidase in unmanipulated SSc
patient monocytes is shown by the translocation of NADPH oxidase
cytosolic components p47phox and p67phox to the light membrane
fractions. Resting monocytes from normal controls (N) and from
scleroderma patients (P) were fractionated, the light membranes were
subjected to SDS 12% polyacrylamide gel electrophoresis and then
immunoblotted with anti-p47phox and anti-p67phox specific antibodies.
Monocytes of normal subjects stimulated with PMA are shown as positive
control. (A) and (B) show two experiments performed with cells from
distinct patients and controls. Normal loading of proteins was assessed by
staining with 0.05% (vol/vol) Ponceau S. See Materials and Methods
for details.
Figure 4. Enhanced translocation of p47phox and p67phox to the light
membrane fractions of monocytes of SSc patients is confirmed by
densitometric analysis. The figure shows the densitometric analysis
performed by laser densitometric scanning on the film of the
immunoblotting of Fig 3. DIU, densitometric image units.
spontaneous generation of superoxide anion, monocytes of sclero-
derma patients were incubated with 25 µM of diphenylene
iodonium. The generation of superoxide, estimated using the
cytochrome c reduction method, is completely inhibited
(Table IV). Treatment with 50 µM of rotenone (Sigma), a
mitochondrial oxidase inhibitor, failed to reduce the superoxide
production, indicating that mitochondrial respiration oxidases have
no role in the generation of O2·
–.
PMA-stimulated monocytes of SSc and PRP patients gener-
ate higher amounts of superoxide than control
monocytes It is known that the production of oxygen free
radicals by phagocytes in response to a stimulant is enhanced if
the cells are previously exposed to a substimulatory dose of an
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Figure 5. Scleroderma monocytes stimulated with PMA generated
higher amounts of superoxide than control monocytes. N, healthy
controls. The difference between healthy control and PRP monocytes is
not statistically significant. Solid and open symbols indicate female and
male patients, respectively. The horizontal bars indicate the median values.
Table IV. Incubation of SSc monocytes with diphenylene
iodonium but not with Rotenone inhibits the generation
of superoxide (expressed as nMol O2·
– per 30 min per 106
monocytes)
Untreated w/superoxide dismutase w/diphenylene w/Rotenone
300 U per ml iodonium 20 µM 50 µM
SSc1 3.5 0 0 3.4
SSc2 5.0 0 1 5.1
SSc3 4.7 0 1.2 4.2
heterologous agonist (Rossi, 1986; Bastian and Hibbs, 1994).
Because SSc patient monocytes are in a state of preactivation, we
have investigated whether in these cells the superoxide anion
production in response to PMA was enhanced. Figure 5 illustrates
that upon stimulation with PMA the median amount of O2·
–
generated by SSc patient monocytes (18.30 nmol per 30 min per
106 cells; 95% confidence interval, 13.30–22.09) is higher than that
released by PRP patient cells (11.85 nmol O2·
– per 30 min per
106 cells; 95% confidence interval, 5.18–14.01) (p 5 0.004) and
by normal controls (11.90 nmol O2·
–; 95% confidence interval,
9.40–14) (p 5 0.01). No difference is evident when controls are
compared with PRP patients (p 5 0.4).
As for PMA-stimulated PMN, cells of patients with SSc and
PRP produce a significant higher amount of superoxide than
controls (median values, 46.5 nmol O2·
– per 30 min per 106 cells,
43 nmol O2·
– per 30 min per 106 cells, and 34.3 nmol O2·
– per
30 min per 106 cells, respectively; SSc versus normals, p 5
0.003; PRP versus normals, p 5 0.04; SSc versus PRP, p 5 not
significant) (Fig 6).
DISCUSSION
In this report we show that (i) monocytes of scleroderma patients
release in vitro, albeit unmanipulated, amounts of superoxide anions
higher than controls; (ii) in scleroderma patients monocytes release
more O2·
– than PMN; (iii) the release in vitro of O2·
– occurs
through the activation of NADPH oxidase; and finally (iv) O2·
–
generation by monocytes is greater in patients with diffuse SSc and
a disease duration of 5 y or less.
In recent years it has been proposed that free radicals may play
a role in the pathogenesis of scleroderma (Murrel, 1993). This
Figure 6. Scleroderma PMN stimulated with PMA generate higher
amounts of superoxide than healthy controls. N, healthy controls. The
difference between scleroderma and PRP monocytes was not statistically
significant. Solid and open symbols indicate female and male patients,
respectively. The horizontal bars indicate the median values.
assumption is mainly based upon indirect evidence. Firstly, a good
proportion of people exposed to agents that generate free radicals,
like bleomycin, L-5-hydroxytryptophan, rapeseed oil, silicone, and
silica dust, may develop scleroderma-like lesions (Rodnan et al,
1967; Finch et al, 1980; Sternberg et al, 1980; Kilbourne et al,
1983; Varga et al, 1989). Secondly, data suggestive for increased
oxidative damage in scleroderma have been reported by several
groups (Lau et al, 1992; Herrick et al, 1994; Bruckdorfer et al,
1995; Stein et al, 1996), although no experimental explanation has
been provided regarding the cellular and the biochemical source
of the oxygen free radicals involved. In this respect our findings
are consistent with the hypothesis that in SSc patients monocytes
contribute, surprisingly more than PMN, to the abnormal oxidative
stress documented in this disorder.
In SSc patients, activation of monocyte respiratory burst may be
induced by the chain reaction that follows ischaemia-reperfusion
events, likely to occur in these patients suffering from Raynaud’s
phenomenon (see Bulkley, 1994 for more details). If it is ischaemia
that leads to superoxide production by circulating monocytes,
however, it has to be explained why (i) monocytes of patients with
primary Raynaud’s phenomenon, who suffer from a vasospastic
disorder of the extremities, did not show increased generation of
superoxide; (ii) generation of superoxide by unmanipulated PMN
of scleroderma patients was considerably less than that by monocytes
of the same patients, despite both cell types were suffering from
the same ischaemic insult. In view of these considerations, it can
be speculated that monocyte NADPH of SSc patients is directly
activated in vivo by factor(s), other than ischaemia.
Monocyte activation is a complex phenomenon regulated
through enhancing and suppressive signals and the phenotype
therefore reflects the net sum of activation and deactivation. In
SSc patients, monocyte activation may be maintained by one or
more enhancing signals, such as IL-1, IL-6, IL-8, and TNF-α,
which are increased in SSc patients (White, 1996) and are known
to trigger the activation of NADPH oxidase (Bastian and Hibbs,
1994). Alternatively, it can be conceived as a default of deactivating
mechanisms of monocytes. Because TGF-β and IL-10 markedly
suppress the release of reactive oxigen species (Tsunawaki et al,
1988; Bogdan et al, 1991), in preliminary experiments we have
evaluated the amounts of TGF-β and IL-10 generated in vitro by
monocytes of SSc patients and found no difference in comparison
with controls (data not shown). The physiologic relevance of this
finding, however, in particular whether the amount of TGF-β and
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IL-10 produced is inadequate to suppress reactive oxygen species
production, is currently under investigation.
The complexity of monocyte activation is further suggested by
the fact that different cytokines, though sharing the same signaling
pathway, are able to induce different patterns of gene expression
and that distinct monocyte functions (e.g., growth and respiratory
burst) may be differently modulated by a single citokine (Gordon
et al, 1995). This is in keeping with our findings that an increased
respiratory burst in monocytes of SSc patients is not paralleled by
an increase in integrin expression (Table II) and TNF-α production
(data not shown).
In this study we also demonstrate that, in monocytes of SSc
patients, superoxide anion generation is sustained through the
activation of the NADPH oxidase. In fact, in unmanipulated
monocytes of scleroderma patients the amount of the cytosolic
NADPH oxidase components p47phox and p67phox translocated on
the plasma membrane is increased, indicating that the enzyme is in
an active state (Clark et al, 1990; De Leo and Quinn, 1997). This
demonstrates that, as observed for PMN, p47phox and p67phox
translocate to the plasma membrane of activated human monocytes.
A very interesting phenomenon, which is relevant for the
mechanism of NADPH oxidase activation, is the potentiation of
the production of oxygen free radicals in response to a stimulant
by prior exposure of the cells to a substimulatory dose of an
heterologous agonist (Rossi, 1986; Bastian and Hibbs, 1994). Such
a ‘‘priming’’ effect could have a physiologic role in inflammation
and defenses against infections. In fact, cells that have been in
contact with very low concentrations of inflammation mediators
or with bacterial products, may be predisposed to an higher release
of toxic oxygen derivatives. Interestingly, in this study we report
that SSc patients monocytes are in a primed state, as demonstrated
by the increased O2·
– production upon stimulation with phorbol
esters. Immune complexes, bacteria, cytokines such as IL-1, IL-6,
IL-8, and TNF-α, and Fc fragments of immunoglobulins, are all
capable of inducing this primed condition in which subsequent
stimulation produces an enhanced NADPH activity (Bastian and
Hibbs, 1994).
Thus, in scleroderma, unknown agonist(s), probably the same
responsible for the NADPH oxidase activity observed in unmanipul-
ated phagocytes of SSc patients, predispose monocytes to respond
to a second stimulation with an augmented NADPH oxidase
activation that increases the oxidative damage in cells of SSc patients.
The molecular mechanisms of the priming phenomenon remain
to be established. The finding that in untreated monocytes of SSc
patients the translocation of p47phox and p67phox to the plasma
membrane is increased, however, may suggest that a preassociation
of a fraction of cytosolic NADPH oxidase components with the
cytochrome b558 could, in some way, predispose the enzyme to
perform a more efficient electron flow through the plasma mem-
brane in response to a subsequent cell stimulation. Obviously,
further investigations are required to test this hypothesis.
Finally, patients with diffuse cutaneous involvement and a disease
duration of 5 y or less showed an increased production of superoxide
when compared with patients with longer disease duration. If this
is confirmed in a larger cohort of patients it would suggest that
monocyte activation may be an early event in the natural history
of the disease and pathologically relevant at least in this subset
of patients.
As discussed by Murrel (1993), oxidative stress can explain the
tissue lesions occurring in scleroderma, as free radicals can induce
endothelial cell injury through peroxidation of lipid components
of cell membrane (Del Maestro et al, 1980; Inaunen et al, 1989)
and may stimulate fibroblasts to proliferate (Murrel et al, 1990) and
to produce increased amounts of collagen (Chojkier et al, 1989).
Furthermore, recently, the autoantigens targeted in diffuse sclero-
derma have been found susceptible to cleavage by reactive oxygen
species, in a metal-dependent manner, providing an explanation
for the appearance of serum antibodies against topoisomerase I and
emphasizing the importance of metal metabolism in the formation
of free radical damage (Halliwell, 1994; Casciola-Rosen et al, 1997).
In conclusion, our findings provide evidence that, through the
activation of an NADPH enzymatic system, monocytes and not
neutrophils contribute to the oxidative stress found in scleroderma.
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